Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6357177 | 1.00 | PPARG (0.48) | PPARGPPARAACESLC6A5GPR34 | |
| SCHEMBL5805960 | 1.00 | PPARG (0.48) | PPARGPPARAACESLC6A5GPR34 | |
| SCHEMBL5805952 | 1.00 | PPARG (0.48) | PPARGPPARAACESLC6A5GPR34 | |
| SCHEMBL5802861 | 0.96 | PPARG (0.45) | PPARGPPARAACESLC6A5GPR34 | |
| SCHEMBL5802869 | 0.96 | PPARG (0.45) | PPARGPPARAACESLC6A5GPR34 | |
| SCHEMBL5802866 | 0.96 | PPARG (0.45) | PPARGPPARAACESLC6A5GPR34 | |
| SCHEMBL5802879 | 0.92 | PPARG (0.49) | PPARGPPARAACEPPARDMEN1 | |
| SCHEMBL5802884 | 0.92 | PPARG (0.49) | PPARGPPARAACEPPARDMEN1 | |
| SCHEMBL5802875 | 0.92 | PPARG (0.49) | PPARGPPARAACEPPARDMEN1 | |
| SCHEMBL5802897 | 0.91 | PPARG (0.46) | PPARGPPARAACEGPR34PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006083266-A1 | INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-10 | — | — | WO | disclosed |
| US-20050250819-A1 | Inhibitors of bacterial type III protein secretion systems | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250819-A1 | Inhibitors of bacterial type III protein secretion systems | PSMB3, GBA3, PSMG3 | PPARG 4386/4885PPARA 4474/4885ACE 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.